A clinical study in metastatic colorectal cancer (CRC) patients demonstrated significantly higher tumour MRP2 expression in non-responders to oxaliplatin-based combination chemotherapy, correlating to elevated ABCC2 mRNA with reduced intracellular drug accumulation and oxaliplatin resistance [42]. The gene discussed is ABCC2; the disease is metastatic colorectal cancer.